Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01727869 | Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer | PHASE1 | COMPLETED | 56 | — | — | Oct 1, 2012 | Jan 1, 2015 | Apr 6, 2015 | 6 | United States |
Safety will be assessed through analysis of laboratory data, physical examination findings and vital signs according to the schedule of assessments, in addition to the spontaneous reporting of adverse events according to CTCAE version 4.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | Dosing regimen 1: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab |
| Cohort 2 | EXPERIMENTAL | Dosing regimen 2: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab |
| Cohort 3 | EXPERIMENTAL | Dosing regimen 3: REGN1400 or REGN1400 and erlotinib or REGN1400 and cetuximab |
| Name | Type | Description |
|---|---|---|
| REGN1400 | DRUG | - |
| Erlotinib | DRUG | - |
| Cetuximab | DRUG | - |
Inclusion Criteria include, but are not limited to, the following: 1. Confirmed diagnosis of certain unresectable or metastatic cancers 2. Adequate Eastern Cooperative Oncology Group (ECOG) performance status 3. Adequate hepatic, renal and bone marrow function 4. Resolution of toxicity from prior t...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520 / GEH200521 - Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | — | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |